Tracking Neural Deterioration in proNGF-Overexpressing Mice: Hippocampal Serotonergic Dysfunction and Synaptic Loss Drive Neurodegeneration
DOI:
https://doi.org/10.46570/utjms-2025-1901Keywords:
Alzheimer's Disease, animal model, pathways, Transcriptomic profiles, DEG's, nerve growth factor, hippocampus, Gnai1, KCNAB2, neurodegenerationAbstract
ProNGF, the precursor protein of mature nerve growth factor (NGF), plays a complex role in neural signaling and has been implicated in neurodegeneration through its apoptotic signaling with the p75NTR receptor. For example, in Alzheimer's disease increased levels of proNGF are associated with cholinergic neuron loss and excitatory/inhibitory imbalance. This study deploys cutting edge a bioinformatic analyses of RNAseq data from TgproNGF#3 mice models that express furin-resistant proNGF. The TgproNGF#3 mouse mimics the pathological accumulation of the precursor NGF protein observed in these diseased brains. Our analysis revealed that proNGF accumulation in the hippocampus and entorhinal regions leads to early downregulation of genes critical for neuronal communication, such as pion and KCNAB2, and later to the upregulation of stress-related and signaling genes, including Neurod1, Neurod2, and Gnai1. These shifts in gene regulation suggest that while the brain attempts to counteract the excess in proNGF, its delay and inefficacy may contribute to early-stage Alzheimer's disease processes.
References
Levi-Montalcini, R., The nerve growth factor 35 years later. Science, 1987. 237(4819): p. 1154-62.
Zheng, C., et al., Amyloid ?-abrogated TrkA ubiquitination in PC12 cells analogous to Alzheimer's disease. J Neurochem, 2015. 133(6): p. 919-25.
Fasulo, L., et al., ProNGF Drives Localized and Cell Selective Parvalbumin Interneuron and Perineuronal Net Depletion in the Dentate Gyrus of Transgenic Mice. Front Mol Neurosci, 2017. 10: p. 20.
Zhu, M. and D. Saffen, Alzheimer’s disease candidate gene PION is differentially expressed in human prefrontal cortex. Molecular Neurodegeneration, 2012. 7(1): p. S25.
Hempstead, B.L., Commentary: Regulating proNGF action: multiple targets for therapeutic intervention. Neurotox Res, 2009. 16(3): p. 255-60.
Greene, L.A. and D.R. Kaplan, Early events in neurotrophin signalling via Trk and p75 receptors. Curr Opin Neurobiol, 1995. 5(5): p. 579-87.
Meakin, S.O. and E.M. Shooter, The nerve growth factor family of receptors. Trends Neurosci, 1992. 15(9): p. 323-31.
Pedraza, C.E., et al., Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol, 2005. 166(2): p. 533-43.
Sycheva, M., et al., Pro-Nerve Growth Factor Induces Activation of RhoA Kinase and Neuronal Cell Death. Brain Sci, 2019. 9(8).
Hardy, J.A. and G.A. Higgins, Alzheimer's Disease: The Amyloid Cascade Hypothesis. Science, 1992. 256(5054): p. 184-185.
Sheppard, O. and M. Coleman, Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis, in Alzheimer’s Disease: Drug Discovery, X. Huang, Editor. 2020, Exon Publications. Copyright: The Authors.: Brisbane (AU) .
Zhang, H., et al., Interaction between A? and Tau in the Pathogenesis of Alzheimer's Disease. Int J Biol Sci, 2021. 17(9): p. 2181-2192.
Haakonsen, D.L., et al., Stress response silencing by an E3 ligase mutated in neurodegeneration. Nature, 2024. 626(8000): p. 874-880.
?ernotová, D., et al., Linking Social Cognition, Parvalbumin Interneurons, and Oxytocin in Alzheimer's Disease: An Update. J Alzheimers Dis, 2023. 96(3): p. 861-875.
Cherubini, E., et al., The depolarizing action of GABA controls early network activity in the developing hippocampus. Mol Neurobiol, 2011. 43(2): p. 97-106.
Do Carmo, S., B. Kannel, and A.C. Cuello, The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. Cells, 2021. 11(1).
Botterill, J.J., et al., An Excitatory and Epileptogenic Effect of Dentate Gyrus Mossy Cells in a Mouse Model of Epilepsy. Cell Rep, 2019. 29(9): p. 2875-2889.e6.
Mohapel, P., et al., Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging, 2005. 26(6): p. 939-46.
Ioannou, M.S. and M. Fahnestock, ProNGF, but Not NGF, Switches from Neurotrophic to Apoptotic Activity in Response to Reductions in TrkA Receptor Levels. Int J Mol Sci, 2017. 18(3).
Feng, D., et al., Molecular and Structural Insight into proNGF Engagement of p75NTR and Sortilin. Journal of Molecular Biology, 2010. 396(4): p. 967-984.
Becker, E.B.E., et al., Characterization of the c-Jun N-Terminal Kinase-BEL Signaling Pathway in Neuronal Apoptosis. The Journal of Neuroscience, 2004. 24(40): p. 8762.
Niewiadomska, G., A. Mietelska-Porowska, and M. Mazurkiewicz, The cholinergic system, nerve growth factor and the cytoskeleton. Behavioural Brain Research, 2011. 221(2): p. 515-526.
Steelman, L.S., et al., Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 2011(1945-4589 (Electronic)).
Fahnestock, M. and A. Shekari, ProNGF and Neurodegeneration in Alzheimer's Disease. Front Neurosci, 2019. 13: p. 129.
Underwood, C.K. and E.J. Coulson, The p75 neurotrophin receptor. The International Journal of Biochemistry & Cell Biology, 2008. 40(9): p. 1664-1668.
Smyth, G.K., limma: Linear Models for Microarray Data, in Bioinformatics and Computational Biology Solutions Using R and Bioconductor. 2005.
R Core Team, R: A Language and Environment for Statistical Computing. 2025: R Foundation for Statistical Computing.
Sean, D. and P.S. Meltzer, GEOquery: A bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics, 2007.
Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-50.
Xie, Z., et al., Gene Set Knowledge Discovery with Enrichr. Curr Protoc, 2021. 1(3): p. e90.
Chen, E.Y., et al., Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics, 2013. 14: p. 128.
Yu, Y., et al., Distinct forms of amyloid-? moderate sleep duration through NAD + -linked redox metabolism in Alzheimer’s disease. 2025.
He, G., et al., Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature, 2010. 467(7311): p. 95-8.
Guo, Z., et al., In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. Cell Stem Cell, 2014. 14(2): p. 188-202.
Salama, R., et al., Functional classification of GNAI1 disorder variants in C. elegans uncovers conserved and cell-specific mechanisms of dysfunction. bioRxiv, 2025.
Muir, A.M., et al., Variants in GNAI1 cause a syndrome associated with variable features including developmental delay, seizures, and hypotonia. Genet Med, 2021. 23(5): p. 881-887.
De Deurwaerdère, P. and G. Di Giovanni, Serotonin in Health and Disease. Int J Mol Sci, 2020. 21(10).
Di Giovanni, G. and P. De Deurwaerdère, Serotonin research: Crossing scales and boundaries. Neuropharmacology, 2020. 181: p. 108340.
Proepper, C., et al., The Kvbeta2 subunit of voltage-gated potassium channels is interacting with ProSAP2/Shank3 in the PSD. Neuroscience, 2014. 261: p. 133-43.
Satoh, J., et al., Immunohistochemical characterization of gamma-secretase activating protein expression in Alzheimer's disease brains. Neuropathol Appl Neurobiol, 2012. 38(2): p. 132-41.
Jia, E., et al., Transcriptomic profiling of differentially expressed genes and related pathways in different brain regions in Parkinson's disease. Neurosci Lett, 2020. 732: p. 135074.
Dean, B., et al., Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 2002. 7(10): p. 1083-91.
Gray, J.A. and B.L. Roth, Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull, 2007. 33(5): p. 1100-19.
Lopez, L.M., et al., Genes from a translational analysis support a multifactorial nature of white matter hyperintensities. Stroke, 2015. 46(2): p. 341-7.
Silver, M., et al., Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. Neuroimage, 2012. 63(3): p. 1681-94.
Chen, Y.C., et al., A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion. Mol Ther, 2020. 28(1): p. 217-234.
Wu, Z., et al., Brain-Wide Neuroregenerative Gene Therapy Improves Cognition in a Mouse Model of Alzheimer's Disease. Adv Sci (Weinh), 2025. 12(14): p. e2410080.
Dolgacheva, L.P., et al., Serotonergic Regulation in Alzheimer's Disease. Int J Mol Sci, 2025. 26(11).
Marner, L., et al., Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging, 2012. 33(3): p. 479-87.
Smith, G.S., et al., Serotonin Degeneration and Amyloid-? Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits. J Alzheimers Dis, 2023. 96(1): p. 215-227.
Bazzari, F.H. and A.H. Bazzari, BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future? Molecules, 2022. 27(24).
McDade, E., et al., The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol, 2021. 17(11): p. 703-714.
Imbimbo, B.P. and M. Watling, Investigational BACE inhibitors for the treatment of Alzheimer's disease. Expert Opin Investig Drugs, 2019. 28(11): p. 967-975.
Ohno, M., Accelerated long-term forgetting: A sensitive paradigm for detecting subtle cognitive impairment and evaluating BACE1 inhibitor efficacy in preclinical Alzheimer's disease. Front Dement, 2023. 2: p. 1161875.
Vassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther, 2014. 6(9): p. 89.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nicole A. Bell, Ali S. Imami, Mahathi Srivatsan, Noah Jiang, Anya Musalgavkar, Ali Ridi, Robert E. McCullumsmith (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
